Postmenopausal Osteoporosis Treatment Global Market Report 2024

The postmenopausal osteoporosis treatment market size has grown strongly in recent years. It will grow from $9.49 billion in 2023 to $10.03 billion in 2024 at a compound annual growth rate (CAGR) of 5.7%. The expansion observed in the historical period can be attributed to factors such as the aging population, the use of hormone replacement therapy, increased awareness of postmenopausal osteoporosis, efforts to reduce fracture risks, and the utilization of nutritional supplements.

The postmenopausal osteoporosis treatment market size is expected to see strong growth in the next few years. It will grow to $12.38 billion in 2028 at a compound annual growth rate (CAGR) of 5.4%. The anticipated growth in the forecast period can be attributed to factors such as healthcare infrastructure growth, increased screening programs, precision medicine approaches, the use of biosimilars in osteoporosis treatment, initiatives focused on bone health in women's health programs, the integration of digital health, and the exploration of regenerative medicine approaches. Major trends in the forecast period include advances in diagnostics, new drug development, emerging therapies, collaborations for drug development, and the integration of artificial intelligence (AI).

The projected increase in osteoporosis prevalence is expected to drive the growth of the postmenopausal osteoporosis treatment market. Osteoporosis, characterized by reduced bone mass and weakened bone tissue, poses an increased risk of fractures. Postmenopausal osteoporosis treatment plays a crucial role in preventing or managing the condition, reducing fracture risks, and enhancing overall health outcomes. A report from Healthy Bones Australia revealed a rise in fractures related to osteoporosis or osteopenia from 178,439 in 2021 to 183,105 in 2022, emphasizing the need for effective postmenopausal osteoporosis treatments.

The growing prevalence of obesity is anticipated to contribute to the expansion of the postmenopausal osteoporosis treatment market. Obesity, characterized by excessive body fat accumulation, negatively impacts health. Postmenopausal osteoporosis treatment offers benefits to individuals with obesity by improving bone density, reducing fracture risks, and promoting bone health. In England, a government report indicated that 25.9% of individuals aged 18 and older were obese in 2021–2022, emphasizing the significant market potential for postmenopausal osteoporosis treatments.

The growth of the postmenopausal osteoporosis treatment market is expected to be propelled by government initiatives focused on symptom management and disease treatment. These initiatives encompass policies, programs, or measures aimed at addressing specific health issues and achieving targeted goals. Notably, the Asia Pacific Consortium on Osteoporosis (APCO) introduced clinical practice guidelines in January 2021 for postmenopausal osteoporosis diagnosis, management, and screening. These guidelines, supported by government and other organizations, provide crucial information for patients' self-care and emphasize the need for monitoring and improving osteoporosis care quality.

Innovation in product offerings emerges as a prominent trend in the postmenopausal osteoporosis treatment market. Key market players are actively introducing new products to maintain their market positions. Theramex, a UK-based pharmaceutical company, launched Livogiva in January 2021, designed specifically for osteoporosis patients. This product expands the company's lineup, offering a range of treatments from prevention with calcium and vitamin D to advanced oral bisphosphonates with patient-friendly administration instructions.

Major companies in the postmenopausal osteoporosis treatment market are striving to gain a competitive edge through innovative products. Advanced bone-building medications, typically administered through injections to promote bone health and density, are a focus of development. In November 2023, Teva Pharmaceuticals Inc., a U.S-based pharmaceutical company, received FDA approval for Forteo (teriparatide injection), catering to postmenopausal women with osteoporosis at high fracture risk. The approval underscores the significance of innovative bone-building medications in treating osteoporosis in both men and women.

Major companies operating in the postmenopausal osteoporosis treatment market report are Pfizer Inc., Johnson and Johnson, F. Hoffmann-La Roche AG, Merck and Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi SA, Eli Lilly and Company, Amgen Inc., Asahi Kasei Corporation, Viatris Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Sandoz International GmbH, Fresenius Kabi AG, Daiichi Sankyo Company Ltd., Sun Pharmaceutical Industries Ltd., Cipla Inc., Dr.Reddys Laboratories Ltd., Hikma Pharmaceuticals PLC., Amneal Pharmaceuticals LLC, Zydus Lifesciences Ltd., Takeda Pharmaceutical Company Limited, Lupin Limited, Celltrion Inc., Biocon Limited, Accord Healthcare Ltd, Ligand Pharmaceuticals Incorporated, Torrent Pharmaceuticals Limited.

North America was the largest region in the postmenopausal osteoporosis treatment market in 2023. The regions covered in the postmenopausal osteoporosis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the postmenopausal osteoporosis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The main types of drugs used in postmenopausal osteoporosis treatment include bisphosphonates, vitamin D3, estrogen agonists or antagonists, hormone replacement therapy, parathyroid hormone therapy, and others. Bisphosphonates, a class of medications, are commonly used to treat various bone-related conditions, with osteoporosis being a notable example. These medications can be administered through oral, parenteral, and other routes, and they are available through various distribution channels, including hospital pharmacies, retail pharmacies, and others.

The postmenopausal osteoporosis treatment market research report is one of a series of new reports that provides postmenopausal osteoporosis treatment market statistics, including postmenopausal osteoporosis treatment industry global market size, regional shares, competitors with a postmenopausal osteoporosis treatment market share, detailed postmenopausal osteoporosis treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the postmenopausal osteoporosis treatment industry. This postmenopausal osteoporosis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.


The postmenopausal osteoporosis treatment market consists of revenues earned by entities by providing screening and diagnosis, bone density testing, and risk assessment. The market value includes the value of related goods sold by the service provider or included within the service offering. The postmenopausal osteoporosis treatment market also includes sales of selective estrogen receptor modulators and osteoporosis drugs that are used for the treatment of postmenopausal osteoporosis. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).


The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.